SCHEMBL22018700

SCHEMBL22018700

CC1(C)OC1COCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.52
TAAR1 Q96RJ0 1/20 0.47
LMNA P02545 1/20 0.47
ALDH1A1 P00352 2/20 0.40
BCHE P06276 2/20 0.40
ACHE P22303 2/20 0.40
IDO1 P14902 1/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSK P43235 1/20 0.39
PTPN1 P18031 1/20 0.39
CDC25B P30305 1/20 0.39
AGXT P21549 1/20 0.38
POLB P06746 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10737065 0.88 TSHR (0.44) TSHRTAAR1LMNAALDH1A1BCHE
SCHEMBL10737057 0.88 TSHR (0.44) TSHRTAAR1LMNAALDH1A1BCHE
SCHEMBL10978460 0.85 TSHR (0.48) TSHRTAAR1LMNAALDH1A1BCHE
SCHEMBL10978467 0.85 TSHR (0.48) TSHRTAAR1LMNAALDH1A1BCHE
SCHEMBL15892809 0.84 TSHR (0.47) TSHRTAAR1LMNAALDH1A1BCHE
SCHEMBL15892812 0.84 TSHR (0.47) TSHRTAAR1LMNAALDH1A1BCHE
SCHEMBL28213842 0.82 TSHR (0.45) TSHRTAAR1LMNAALDH1A1BCHE
SCHEMBL7348857 0.82 TSHR (0.41) TSHRTAAR1LMNAALDH1A1ACHE
SCHEMBL7348863 0.82 TSHR (0.41) TSHRTAAR1LMNAALDH1A1ACHE
SCHEMBL15892796 0.80 TSHR (0.42) TSHRTAAR1LMNAALDH1A1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11185592-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2021-11-30 US disclosed
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2021-04-15 US disclosed
US-10660968-B2 Spirocyclic degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2020-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11185592-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A TSHR 1113/4885TAAR1 3577/4885LMNA 1938/4885
US-20210106688-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION STUB1, UBE3C, UBE3A TSHR 1113/4885TAAR1 3577/4885LMNA 1938/4885
US-10660968-B2 Spirocyclic degronimers for target protein degradation STUB1, UBE3C, UBE3A TSHR 1113/4885TAAR1 3577/4885LMNA 1938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.